LL-37 2 mg/mL Injection recalled over sterility concerns
- Recall date
- April 5, 2022
- Source
- U.S. Food & Drug Administration (FDA) — enforcement report
- Official notice title
- North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding recalls LL-37 2 mg/mL (5 mL) Injection, 5 mL vials, Rx only, Farmakeio 1736 N Greenville Ave Richardson, TX 75081 USA
- Recall number
- D-0778-2022
- FDA classification
- Class II
- Brand / firm
- North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding
- Sold / distributed
- Nationwide within United States
Why it was recalled
Lack of Assurance of Sterility: deviations from Current Good Manufacturing Practices (CGMP) that call into question the sterility of products intended to be sterile.
Class II means using this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What was recalled
LL-37 2 mg/mL (5 mL) Injection, 5 mL vials, Rx only, Farmakeio 1736 N Greenville Ave Richardson, TX 75081 USA
Get recall alerts
Free email alert whenever North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding has a new recall — straight from official government data. Unsubscribe anytime.
More recalls from: North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding